Advances in Therapy
Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.
Advances in Therapy is of interest to a broad audience of researchers, industry and healthcare professionals, receiving submissions from all over the world, and publishes original research and authoritative reviews focusing on new and existing therapies and interventions, areas of unmet need and general topics of interest to the medical community.
Moving forward from traditional publishing, Advances in Therapy offers a range of additional features designed to increase visibility and readership. Each paper is accompanied by a bulleted slide summary, giving a time-efficient overview of the content to a wider readership. Articles also have the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are open access and are peer reviewed to the same high standard as the article itself.
Upon acceptance of your article for publication, you will be required to pay an article processing charge of £420/$660 per typeset page. Additionally, Advances in Therapy offers an open access option for all articles submitted to the journal. If you choose open access publication you will be required to pay an additional fee of £2000/$3000 upon acceptance of your article.
Please note: Advances in Therapy's open access articles are published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0.
For more information about the journal, please contact firstname.lastname@example.org.
Real-world Evidence for the Antianginal Efficacy of Trimetazidine from the Russian Observational CHOICE-2 Study
Maria Glezer (February 2017)
- Journal Title
- Advances in Therapy
- Volume 17 / 2000 - Volume 34 / 2017
- Print ISSN
- Online ISSN
- Springer Healthcare
- Additional Links
- Industry Sectors
To view the rest of this content please follow the download PDF link above.